Clinical trials: Hydroxychloroquine
COVID-19, Favipiravir
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
This is an open-label, non-randomized clinical trial study. The number of 40 COVID-19 patients with moderate severity will be admitted in progressive care units (PCUs) and intensive care units (ICUs) enrolled in the study.
- Conditions
- COVID-19, Favipiravir, Kaletra, Hydroxychloroquine
- Trial name
- NCT04376814
- Testing
- Favipiravir, Hydroxychloroquine, Lopinavir / Ritonavir
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Baqiyatallah Medical Sciences University
Cystic Fibrosis
Hydroxychloroquine in Cystic Fibrosis
Study levels of inflammatory mediators in induced sputum of patients with cystic fibrosis before and after a 4 week course of oral hydroxychloroquine.
- Trial name
- NCT00311883
- Testing
- hydroxychloroquine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University
Ivermectin, Hydroxychloroquine
A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
COVID19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there is no specific medication against it. Like other countries of the world, Bangladesh is also struggling in the case of treatment of this disease.
- Conditions
- Ivermectin, Hydroxychloroquine, COVID19
- Trial name
- NCT04434144
- Testing
- Ivermectin + Doxycycline, Hydroxychloroquine + Azithromycin
- Where
- Bangladesh
- Volunteers
- 116 people
- Sponsor
- Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar
Malignant Solid Tumour
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and to…
- Trial name
- NCT01023737
- Testing
- Hydroxychloroquine, Vorinostat
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Immune Thrombocytopenia With Positive ANA Antibodies
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus thrombopoietin receptor agonists (TPO-RA) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults.
- Trial name
- NCT06479291
- Testing
- Hydroxychloroquine Oral Tablet, Eltrombopag
- Where
- 7 sites in China, Hong Kong and 1 more
- Volunteers
- 126 people
- Sponsor
- Yunfeng Cheng
Graft Versus Host Disease
Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease
RATIONALE: Hydroxychloroquine may decrease the immune response and be effective in treating chronic graft-versus-host disease. It is not yet known if standard therapy for graft-versus-host disease is more effective with or…
- Trial name
- NCT00031824
- Testing
- cyclosporine, hydroxychloroquine, prednisone
- Where
- 104 sites in United States, Australia and 4 more
- Volunteers
- 82 people
- Sponsor
- Children's Oncology Group
COVID-19
Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk
Few studies have reported the efficacy of HCQ in reducing the viral load and improving the severity of symptoms in hospitalized COVID-19 cases with serious respiratory infection.
- Trial name
- PREVENT (NCT04371926)
- Testing
- Hydroxychloroquine Sulfate
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
Systemic Lupus Erythematosus
Study of Anti-Malarials in Incomplete Lupus Erythematosus
This project is a multicenter, randomized, placebo-controlled, double-blind clinical trial that is designed to test whether treating patients who are at risk for development of lupus with hydroxychloroquine can slow accumulation…
- Trial name
- SMILE (NCT03030118)
- Testing
- Hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 187 people
- Sponsor
- Milton S. Hershey Medical Center
Nonalcoholic Steatohepatitis
Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a serious type of nonalcoholic fatty liver disease (NAFLD), which is characterized by lobular inflammation and apoptosis resulting from hepatic steatosis in the absence of excessive alcohol…
- Trial name
- NCT05733897
- Testing
- hydroxychloroquine
- Where
- 2 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
COVID-19, Coronavirus
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning
The purpose of this study was to assess the performance of a machine learning algorithm which identifies patients for whom hydroxychloroquine treatment is associated with predicted survival.
- Conditions
- COVID-19, Coronavirus, Mortality
- Trial name
- IDENTIFY (NCT04423991)
- Testing
- COViage
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Dascena
Alport Syndrome, X-Linked
Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
This Phase 2 randomized controlled trial will study the safety, tolerability, and efficacy of Hydroxychloroquine in qualified patients with Alport syndrome.
- Trial name
- CHXLAS (NCT04937907)
- Testing
- Hydroxychloroquine Sulfate 100 milligram (mg) Tab, Benazepril hydrochloride 10 milligram (mg) Tab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Children's Hospital
COVID-19, Coronavirus Infection
Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment
Chloroquine or hydroxychloroquine in COVID-19 treatment
- Trial name
- NCT04353336
- Testing
- Chloroquine or Hydroxychloroquine
- Where
- Egypt
- Volunteers
- 194 people
- Sponsor
- Tanta University
LIPIN1 Deficiency
Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency
Lipin-1 deficiencies are responsible for severe rhabdomyolysis and muscle pain in childhood. A specific treatment does not exist.
- Trial name
- LIPIN-1-METAB (NCT04007562)
- Testing
- Hydroxychloroquine Sulfate
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with…
- Conditions
- Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
- Trial name
- NCT04201457
- Testing
- Dabrafenib, Trametinib, Hydroxychloroquine
- Where
- 15 sites in United States
- Volunteers
- 57 people
- Sponsor
- Pediatric Brain Tumor Consortium
Pre-Eclampsia
Hydroxychloroquine May be Beneficial for Preeclampsia
The purpose of this research is to investigate the impact of hydroxychloroquine on the incidence of hypertensive pregnancy disorders in women with a history of recurrent spontaneous abortion (RSA).
- Trial name
- NCT06020378
- Testing
- Hydroxychloroquine
- Where
- China
- Volunteers
- 462 people
- Sponsor
- RenJi Hospital
COVID-19
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection
Background: In December 2019, patients with pneumonia secondary to a new subtype of Coronavirus (COVID-19) were identified in China. In a few weeks the virus spread and cases started practically all over the world.
- Trial name
- NCT04391127
- Testing
- Hydroxychloroquine, Ivermectin
- Where
- Mexico
- Volunteers
- 108 people
- Sponsor
- Centenario Hospital Miguel Hidalgo
Rheumatic Diseases
Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine
Hydroxychloroquine (HCQ) is a disease-modifying, anti-rheumatic drug that regulates immune system activity and is typically prescribed to treat rheumatoid arthritis and systemic lupus erythematosus, as well as other immune…
- Trial name
- NCT04310462
- Testing
- New e-prescribing interface
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Breast Cancer
Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients
Hydroxychloroquine is a drug that has been used to treat malaria and rheumatism. It is recently discovered that Hydroxychloroquine increases 'autophagy'.
- Trial name
- NCT01292408
- Testing
- Hydrochloroquine
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Pregnancy Related, COVID
Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum
It still unclear how SARS-CoV-2 affects pregnant women and their offspring, as well as which factors may influence obstetrical disease and outcomes, including the timing of maternal viral exposure by gestational age, the effects…
- Conditions
- Pregnancy Related, COVID, Covid-19
- Trial name
- COVID-Preg (NCT04410562)
- Testing
- Hydroxychloroquine
- Where
- 9 sites in Spain
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Interstitial Lung Disease, Diffuse Parenchymal Lung Disease
Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)
This is an exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.
- Conditions
- Interstitial Lung Disease, Diffuse Parenchymal Lung Disease, Children´s Interstitial Lung Disease
- Trial name
- HCQ-chILD-EU (NCT02615938)
- Testing
- Hydroxychloroquine sulfate
- Where
- 9 sites in Germany
- Volunteers
- 35 people
- Sponsor
- Matthias Griese